Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia

Pharmacogenomics Journal

Volumn 12, Issue 5, 2012, Pages 386-394

  Ansari, M ^a,b   Sauty, G ^a   Labuda, M ^a   Gagne V ^a   Rousseau, J ^a   Moghrabi, A ^a,c   Laverdiere C ^a,c   Sinnett, D ^a,c   Krajinovic, M ^a,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

childhood leukemia; multidrug resistance associated proteins; outcomes; pharmacogenetics; polymorphisms; treatment

Indexed keywords

CYTARABINE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; GENE; GENE ACTIVITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MRP2 GENE; MRP3 GENE; MRP5 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REGULATOR GENE; REPORTER GENE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ALLELES; BIOMARKERS, PHARMACOLOGICAL; DISEASE-FREE SURVIVAL; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84866740518     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.17     Document Type: Article

References (55)

1. Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr 2007; 19: 15-22.
2. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117-129.
3. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257-268.
4. Ansari M, St-Onge G, Krajinovic M. [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris) 2007; 23: 961-967.
5. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9: 227-246.
6. Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 2007; 46: 449-470.
7. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457-473.
8. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 2005; 15: 523-533.
9. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26: 153-181.
10. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999; 59: 2532-2535.
11. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005; 65: 4425-4430.
12. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96: 6914-6919.
13. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 7225-7232.
14. Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I et al. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 2003; 278: 6680-6686.
15. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metabolism Rev 2008; 40: 317-354.
16. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A et al. Polymorphisms in multidrug ressistance-associated protein Gene 4 is Associated with outcome childhood acute lymphoblastic leukemia. Blood 2009; 114: 1383-1386.
17. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C et al. Results of the Dana-Farber cancer institute ALL consortium protocol 95-for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
18. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14: 2247-2256.
19. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
20. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
21. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006; 91: 1113-1116.
22. Bourgeois S, Labuda D. Dynamic allele-specific oligonucleotide hybridization on solid support. Anal Biochem 2004; 324: 309-311.
23. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Human Genet 2001; 68: 978-989.
24. Storey JD, Taylor JE, Siegmund D. Strong control, conservative point estimation, and simultaneous conservative consistency of false discovery rates: a unified approach. J R Stat Soc Ser B 2004; 66: 187-205.
25. Takada T, Suzuki H, Sugiyama Y. Characterization of 50-flanking region of human MRP3. Biochem Biophys Res Commun 2000; 270: 728-732.
26. Dulucq S, St-Onge G, Gagne V, Ansari M, Sinnett D, Labuda D et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 2008; 111: 3692-3700.
27. Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B et al The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003; 102: 4493-4498.
28. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 2003; 9: 1083-1086.
29. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, Sugiyama Y. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J Pharmacol Exp Ther 2008; 327: 465-473.
30. Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet Genomics 2008; 18: 823-833.
31. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004; 14: 155-164.
32. Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leukemia Res 2008; 32: 919-929.
33. Muller PJ, Dally H, Klappenecker CN, Edler L, Jager B, Gerst M et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009; 124: 1669-1674.
34. Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism-211C4T in the regulatory region of the human ABCC3 gene. Life Sci 2007; 80: 1490-1494.
35. Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D. In acute leukemia, the polymorphism-211C4T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene. Pharmacogenet Genomics 2006; 16: 149-150.
36. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004; 10: 1295-1312.
37. Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG et al. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol 2007; 85: 1-10.
38. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65: 11419-11428.
39. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129: 349-360.
40. Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008; 107: 1518-1528.
41. Berezowski V, Landry C, Dehouck MP, Cecchelli R, Fenart L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res 2004; 1018: 1-9.
42. Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, Feng B et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009; 59: 404-413.
43. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7: 56-65.
44. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 2011; 11: 25-34.
45. NaesensM, Kuypers DR, Verbeke K, Vanrenterghem Y.Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-1084.
46. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147.
47. Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, Chon CY et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007; 17: 403-415.
48. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80: 468-476.
49. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18: 357-365.
50. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35: 572-579.
51. Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-808.
52. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
53. Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey AJ et al. Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 2006; 16: 439-450.
54. Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M et al. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol 2003; 163: 1567-1577.
55. Stojic J, Stohr H, Weber BH. Three novel ABCC5 splice variants in human retina and their role as regulators of ABCC5 gene expression. BMC Mol Biol 2007; 8: 42.